中国神经再生研究(英文版) ›› 2026, Vol. 21 ›› Issue (2): 542-552.doi: 10.4103/NRR.NRR-D-24-00797

• 综述:视神经损伤修复保护与再生 • 上一篇    下一篇

用于视网膜疾病治疗的创新基因递送系统

  

  • 出版日期:2026-02-15 发布日期:2025-05-20
  • 基金资助:
    国家自然科学基金(82301216)和上海市自然科学基金(STCSM23ZR1457500)。

Innovative gene delivery systems for retinal disease therapy

Hongguang Wu# , Ling Dong# , Shibo Jin, Yongwang Zhao* , Lili Zhu*   

  1. Department of Ophthalmology, Songjiang Hospital and Songjiang Research Institute, Shanghai Key Laboratory of Emotions and Affective Disorders, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Online:2026-02-15 Published:2025-05-20
  • Contact: Yongwang Zhao, PhD, zywang1@126.com; Lili Zhu, PhD, lili.zhu@shsmu.edu.cn.
  • Supported by:
    This work was supported by the National Natural Science Foundation of China, No. 82301216 (to LZ); the Natural Science Foundation of Shanghai, No. STCSM23ZR1457500 (to LZ).

摘要:

人类视网膜是一种复杂而高度特化的结构,由各种类型的细胞组成,这些细胞协同工作,产生和传输视觉信号。然而,遗传倾向和与年龄有关的退化会导致视网膜损伤,严重损害视力或导致失明。一直以来,视网膜疾病的治疗方案都很有限,因此迫切需要创新的治疗策略。细胞和基因疗法的最新进展已成为应对这些挑战的有希望的方法,其中一个关键因素是将治疗基因输送到目标视网膜细胞的输送系统的有效性。为此,文章重点介绍用于治疗视网膜疾病的两大类基因递送载体:病毒和非病毒系统。①病毒载体包括慢病毒和腺相关病毒,利用病毒天生具有的浸润细胞的能力,将治疗性遗传物质导入靶细胞进行基因矫正。慢病毒可容纳长达8 kb的外源基因,但其与宿主基因组的整合机制引起了人们对插入突变风险的担忧。相反,腺相关病毒作为外显子体存在于细胞核中,安全性显著提高,但其有限的包装能力限制了其在较窄疾病谱上的应用,因此有必要探索替代的递送方法。与此同时,该领域在开发新型非病毒递送系统,特别是基于脂质体技术的系统方面也取得了重大进展。研究人员巧妙地控制了脂质体中亲水分子和疏水分子的比例,或开发出新的脂质配方,从而创造出先进的非病毒载体。这些创新系统包括固体脂质纳米颗粒(SLNs)、聚合物纳米颗粒、树枝状分子、聚合物胶束和聚合物纳米颗粒。②与病毒递送系统相比,非病毒递送系统的负载能力明显增强,可将核酸、mRNA 或蛋白质分子直接递送到细胞中。这种机制有效地绕过了DNA转录和处理过程,显著提高了治疗效率。不过,由于非病毒微粒系统具有免疫原性和潜在蓄积毒性,因此有必要对其进行不断优化,以减少其在体内的不良影响。③文章深入探讨了用于视网膜治疗的各种递送系统,详细介绍了每种载体类型的特点、优势、局限性和临床应用,旨在指导选择适合特定视网膜疾病的最佳递送工具,最终提高治疗效果,改善患者预后,同时为更有效、更有针对性的视网膜治疗干预提供参考依据。

https://orcid.org/0009-0003-4119-5270 (Lili Zhu); https://orcid.org/0000-0002-0473-3426 (Yongwang Zhao)

关键词: 腺相关病毒, 递送系统, 基因递送, 基因治疗, 慢病毒, 纳米颗粒递送, 非病毒递送, 视网膜, 视网膜疾病, 小分子递送

Abstract: The human retina, a complex and highly specialized structure, includes multiple cell types that work synergistically to generate and transmit visual signals. However, genetic predisposition or age-related degeneration can lead to retinal damage that severely impairs vision or causes blindness. Treatment options for retinal diseases are limited, and there is an urgent need for innovative therapeutic strategies. Cell and gene therapies are promising because of the efficacy of delivery systems that transport therapeutic genes to targeted retinal cells. Gene delivery systems hold great promise for treating retinal diseases by enabling the targeted delivery of therapeutic genes to affected cells or by converting endogenous cells into functional ones to facilitate nerve regeneration, potentially restoring vision. This review focuses on two principal categories of gene delivery vectors used in the treatment of retinal diseases: viral and non-viral systems. Viral vectors, including lentiviruses and adeno-associated viruses, exploit the innate ability of viruses to infiltrate cells, which is followed by the introduction of therapeutic genetic material into target cells for gene correction. Lentiviruses can accommodate exogenous genes up to 8 kb in length, but their mechanism of integration into the host genome presents insertion mutation risks. Conversely, adeno-associated viruses are safer, as they exist as episomes in the nucleus, yet their limited packaging capacity constrains their application to a narrower spectrum of diseases, which necessitates the exploration of alternative delivery methods. In parallel, progress has also occurred in the development of novel non-viral delivery systems, particularly those based on liposomal technology. Manipulation of the ratios of hydrophilic and hydrophobic molecules within liposomes and the development of new lipid formulations have led to the creation of advanced non-viral vectors. These innovative systems include solid lipid nanoparticles, polymer nanoparticles, dendrimers, polymeric micelles, and polymeric nanoparticles. Compared with their viral counterparts, non-viral delivery systems offer markedly enhanced loading capacities that enable the direct delivery of nucleic acids, mRNA, or protein molecules into cells. This bypasses the need for DNA transcription and processing, which significantly enhances therapeutic efficiency. Nevertheless, the immunogenic potential and accumulation toxicity associated with nonviral particulate systems necessitates continued optimization to reduce adverse effects in vivo. This review explores the various delivery systems for retinal therapies and retinal nerve regeneration, and details the characteristics, advantages, limitations, and clinical applications of each vector type. By systematically outlining these factors, our goal is to guide the selection of the optimal delivery tool for a specific retinal disease, which will enhance treatment efficacy and improve patient outcomes while paving the way for more effective and targeted therapeutic interventions.

Key words: adeno-associated viruses, delivery systems, gene delivery, gene therapy, lentivirus, nanoparticle delivery, non-viral delivery, retinal disease, retina, small molecular delivery